Introduction
============

Approximately 24 million Americans have one or more autoimmune disease (e.g. Type I diabetes, systemic lupus erythematosus, autoimmune hepatitis). These chronic and incurable diseases disproportionately affect women, and are among the leading causes of death for young and middle-age women. In order to prevent these chronic incurable diseases we need to know more about the factors that trigger and maintain their pathology.

Effector/memory CD4^+^ T cells that secrete IFN-γ or IL-17 are critical mediators of both idiopathic and experimental autoimmune disease \[[@dvx013-B1], [@dvx013-B2]\]. These CD4^+^ T cells can persist for years in humans and animals without causing disease, while maintaining a memory phenotype, a stable cytokine response pattern, and the capacity for induced autoimmune attack \[[@dvx013-B1]\]. Several adoptive transfer studies have shown that memory CD4^+^ T cells that have differentiated into Th1 or Th17 cells and reactivated can provide crucial help to cytotoxic CD8^+^ T cells, promote generation of pathogenic autoantibodies, and secrete tissue-damaging pro-inflammatory cytokines \[[@dvx013-B3], [@dvx013-B4]\].

Understanding how autoimmune disease triggers differentiation of naïve CD4^+^ T cells into pro-inflammatory effector/memoryTh1 or Th17 cells is important for defining etiology. Twin concordance studies have shown that although genetics may increase susceptibility to autoimmunity, environmental triggers are required to initiate disease. Our work examining the link between the environment and CD4^+^ T cell differentiation has focused on the volatile organic compound trichloroethylene (TCE). Although the use of TCE as a solvent in the USA has declined as its toxicity became more apparent, over 31 million pounds of TCE-containing waste was released or disposed of in this country in the last decade alone (<https://www.epa.gov/toxics-release-inventory-tri-program>). Because of its improper disposal over the years, TCE has contaminated many of the water systems in the USA \[[@dvx013-B5]\].

TCE is one of the first 10 chemicals selected for risk evaluation by the EPA under the newly revised TSCA (Toxic Substances Control Act) (<https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/evaluating-risk-existing-chemicals-under-tsca#chemicalnames>). This list was compiled based on the highest combined hazard, exposure, persistence and bioaccumulation characteristics. One of the most sensitive non-cancer outcomes of TCE exposure is immunotoxicity \[[@dvx013-B6]\]. Specifically, chronic exposure to TCE (occupational or environmental) has been linked to a variety of autoimmune diseases and other hypersensitivity disorders \[[@dvx013-B7]\].

CD4^+^ T cells are especially susceptible to the effects of TCE. Even if overt disease is not diagnosed, increased numbers of activated CD4^+^ T cells are often found in humans exposed to TCE \[[@dvx013-B7], [@dvx013-B16]\]. An expansion of peripheral blood CD4^+^ T cells is also a biomarker for patients with TCE-induced hypersensitivity \[[@dvx013-B20]\]. Finally, as shown by ourselves and others, TCE exposure increased the percentage of effector/memory IFN-γ- and Th17-secreting CD4^+^ T cells in mice that went on to develop CD4^+^ T cell-mediated autoimmune hepatitis \[[@dvx013-B21]\].

It has recently been reported that CD4^+^ T cell differentiation into different effector/memory CD4^+^ T cell subsets (Th1, Th2, Th17 and T~reg~) is at least partially regulated by gene-specific (i.e. *Ifng*, *Il17A*, *Ctla*, *Tnfsf14*, and *Foxp3)* increases or decreases in DNA methylation \[[@dvx013-B24], [@dvx013-B25]\]. This differentiation process can be disrupted during the development of autoimmunity, resulting in inappropriate DNA methylation and associated expression of genes that encode pro-inflammatory cytokines, chemokines, adhesion molecules, or suppressive mediators (e.g. *LTA*, *CD11α*, *CD70*, *CD40L*, *FOXP3*) \[[@dvx013-B26]\]. The dysregulated methylome in autoimmune disease can enhance heterogeneity or plasticity in CD4^+^ T cell subsets that can increase disease severity \[[@dvx013-B35], [@dvx013-B36]\]. For example, the most pathogenic CD4^+^ T cells in models of type 1 diabetes mellitus, arthritis, and multiple sclerosis are those that secrete both IL-17 and IFN-γ, i.e. exhibit a dual Th1/Th17 phenotype \[[@dvx013-B37]\]. Thus, the development of autoimmune disease may represent a breakdown in normal DNA methylation patterns in a manner that increases the differentiation of pathogenic effector/memory CD4^+^ T cells. Demonstrating that a toxicant such as TCE can disrupt the methylome is important for understanding how toxicants promote autoimmunity.

We reported previously that a 12-week exposure to TCE in drinking water altered global methylation in effector/memory CD4^+^ T cells from MRL+/+ mice \[[@dvx013-B38]\]. A subsequent study, using targeted bisulfite next generation sequencing of amplicons generated on a Fluidigm Access Array, examined TCE- and time-dependent changes in DNA methylation associated with 16 functionally important genes in CD4^+^ T cells. TCE was found to increase gene-specific methylation variance in effector/memory CD4^+^ cells \[[@dvx013-B6]\], and to induce a time-dependent cumulative increase in DNA methylation in the CpG sites of the promoter of the *Ifng* gene \[[@dvx013-B39]\].

The methylome is even larger than the transcriptome. Thus, although a gene targeted evaluation of DNA methylation may provide important information about TCE-induced epigenetic alterations of specific genes, it may not recognize more global alterations in the methylome induced by TCE exposure. Consequently, the current study used reduced representation bisulfite sequencing (RRBS) \[[@dvx013-B40]\], for a more comprehensive look at the impact of TCE exposure on CpG sites across the entire genome. A concurrent transcriptomic analysis was conducted so that TCE-induced alterations in DNA methylation could be compared with associated changes in gene expression.

Materials and Methods
=====================

Ethics Statement
----------------

All work was approved by the Animal Care and Use Committee at the University of Arkansas for Medical Sciences, and conformed to the USDA Animal Welfare Act and Regulations.

Mouse Treatment
---------------

Female MRL+/+ mice were selected for this study. Autoimmune disease in humans is known to involve an ill-defined genetic predisposition, and is most often found in women. Young adult female MRL+/+ mice, with a propensity for autoimmunity but absence of overt disease, can be used to mimic these requirements, and are used to test for the ability of different toxicants to trigger or augment autoimmunity as previously described \[[@dvx013-B38]\]. Eight week-old female MRL+/+ mice (Jackson Laboratories; Bar Harbor, ME, USA) were housed in polycarbonate ventilated cages and provided with lab chow (Harlan 7027) and drinking water *ad libitum.* TCE (purity 99+ %; Aldrich Chemical Co. Inc.; Milwaukee, WI, USA) was suspended in drinking water with 1% emulsifier Alkamuls EL-620 from Rhone-Poulenc (Cranbury, NJ). The mice (8--9 mice/group) received either 0 or 0.5 mg/ml TCE in their drinking water for 40 weeks. Freshly made TCE-containing drinking water was provided every 3--4 days. The mice were weighed once a month. On the basis of water intake, body weight and measured TCE degradation in the water bottles the mice were exposed to an average of 40--50 mg/kg/day TCE. This does is occupationally relevant based on the current 8-h Permissible Exposure Limit \[established by the Occupational Safety and Health Administration (OSHA)\] for TCE is 100 ppm or ∼76 mg/kg/day.

CD4^+^ T Cells
--------------

Mice were sacrificed after 40 weeks, and splenic CD4^+^ T cells were isolated using Dynabeads FlowComp Mouse CD4 kit (Invitrogen). The CD4^+^ T cells were then further separated into CD62L^lo^ or CD62L^hi^ CD4^+^ T cell populations using Dynabeads M-280 Streptavidin (Invitrogen) conjugated with biotinylated anti-CD62L antibody (eBiosciences, 13-0621-85). The resulting CD62L^lo^ CD4^+^ T cells (effector/memory CD4^+^ T cells) were stimulated with immobilized anti-CD3 antibody and anti-CD28 antibody for 18 has described \[[@dvx013-B41]\], and the activated CD4^+^ T cells were frozen for subsequent examination of DNA methylation or transcriptomics. To ensure sufficient cells for use in all the assays each sample of CD4^+^ T cells used in the study originated in an equal number of pooled spleen cells from 2 to 3 mice resulting in four samples/treatment group.

DNA Methylation Analysis by RRBS
--------------------------------

DNA from the CD4^+^ T cells (four control samples and four TCE samples) was isolated using the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific). The resulting DNA is tested on the NanoDrop 2000c (Thermo Fisher Scientific) for an A260/A280 range of 1.8--2.0. DNA quality is then confirmed using standard gel electrophoresis. The DNA was then restriction digested, end-repaired, purified, and attached with barcode adapters \[[@dvx013-B42]\]. The RRBS libraries were generated, bisulfite converted, PCR enriched, size selected, purified, and sequenced (2 × 100 paired end) using an Illumina HiSeq sequencer (UAMS Translational Research Institute Genomics Core).

The Fasta files containing sequenced reads were first quality checked using FastQC program v0.11.5 and trimmed for adapter and low-quality sequences using trim galore (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore>/) with a Phred score of 20 as cut-off. Sequences were mapped using paired end mapping to mouse genome assembly mm9 using Bismark software v0.16.1 with Bowtie 2 v2.2.8 short read aligner. In the final step of bismark_methylation_extractor module, C in CpG, CHH and CHG were extracted with the parameter---no_overlap, to ensure that overlapping reads from the paired reads were not measured twice in the final analysis. Additionally, due to detection of consistently higher methylation rate at the ends of the sequencing reads in M-bias plots (data not shown), three bases from the ends of each pair of reads were discounted for methylation extraction. Bismark's methylation_extracter output files were then read into MethylKit R package \[[@dvx013-B43]\] for further statistical analyses.

### Differential Methylation Analysis

A Phred Quality Score (Q) is used to represent the confidence level in assignment of each base call by the sequencer. It is logarithmically related to error probability and gives an estimated probability of a base call being wrong. In bisulfite sequencing a Phred score of 20 is normally used as a cut-off, and is the default value used in many open source sequencing tools \[[@dvx013-B44]\]. Similarly, 10 reads is the minimum number of reads required for accurate determination of DNA methylation if individual CpG sites are analyzed for methylation differences \[[@dvx013-B45]\]. Consequently, only sequence reads with a Phred score \>20 and a minimum of 10 reads per CpG were accepted for downstream statistical analysis. Reads above the 99.9 percentile were also filtered out since these reads are either mapped against repeat elements or have very high PCR bias. A logistic regression model was fitted per CpG site to test for TCE effect on methylation level using a FDR cut off of 5% and a methylation difference of at least 10%.

In order to test the difference between TCE and control mice in terms of the relationship between mean methylation variance and mean percent methylation, quadratic regression models including the quadratic and linear interaction between groups and average percent methylation were fit to the data. A likelihood ratio test was used to compare the TCE and control curves by fitting and comparing a full model and a reduced model. The full model includes quadratic and linear interaction between groups (TCE vs control) and average percent methylation, while the reduced model includes common quadratic and linear terms of average percent methylation for both TCE and control.

qRT-PCR
-------

Fluorescence-based quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was conducted using RNA isolated from effector/memory CD4^+^ T cells using techniques and primers as described \[[@dvx013-B21]\]. Fold differences (log~2~ scale) in expression were determined using expression levels of resting (unactivated) CD4^+^ T cells of the appropriate subset of control mice as the control (1×) expression level. The threshold for statistical significance in fold change was set at *P* \< 0.05. Differences between experimental groups were tested first with analysis of variance (ANOVA), and where the *F* test was significant, subsequent pairwise contrasts were tested using a two-sample *t*-test. CD4^+^ T cell concentration and gene expression values were right-skewed, and therefore these data were log-transformed for statistical analyzes. Adjusting for multiple comparisons, *P*-values from pairwise comparisons that were smaller than the Bonferroni-adjusted significance level indicated statistical significance.

Gene Arrays
-----------

This assessment was conducted by the Genomics Core at the University of Arkansas for Medical Sciences. All RNA samples extracted from CD4^+^ T cells had RIN (RNA integrity number) values of 8.0 or above. Total RNA (500 ng) was converted to cDNA, amplified and biotinylated by use of the Ambion Illumina TotalPrep™-96RNA Amplification Kit (Life Technologies, Carlsbad, CA, USA). Gene expression profiling was performed using the Expression BeadChip System from Illumina (Illumina Inc., San Diego, CA, USA) following the manufacturer's instructions. Raw data were log~2~ transformed and normalized to the median intensity signal of 47 231 genes on the array. After normalization and filtering of low intensity spots, two-sample Student's *t*-tests were performed and these data were plotted against fold-change measurements. Statistical significance was set at false discovery rate (FDR) \< 0.05. Ingenuity Pathway Analysis software (Redwood City, CA, USA) was used for network identification.

Modeling
--------

Fractional Polynomials were fit to model the percentage of total CpG sites that displayed a particular level of mean methylation (e.g. CpG sites that averaged 0--5% methylation or 40--45% methylation). This model has more flexibility to obtain a wide range of shapes of the distribution of the data than regular polynomial models. The power of mean methylation binning were chosen among {-2, -1, -0.5, 0, 0.5, 1, 2, 3} and were allowed to be repeated. The best-fitting first-degree FP model was the one with the lowest deviance among all first-degree powers. The best-fitting second-degree FP model was determined the same way after searching through all possible second-degree power combinations. The final best-fitting model was decided among the four models: null, linear, best-fitting first-degree FP, and best-fitting second-degree FP using a close testing procedure \[[@dvx013-B46]\]. The final sets of powers selected for the best-fitting model for each chromosome in control or TCE groups were then compared. Having the same set of power suggests that the distribution is similar while a different set of powers suggests the distribution is different.

Annotation of the CpGs and Regulatory Elements was done using the University of California, Santa Cruz, Genome Browser (mouse NCBI37/mm9).

Results
=======

Large-Scale Effects of TCE on DNA Methylation in Effector/Memory CD4^+^ T Cells
-------------------------------------------------------------------------------

RRBS analysis of the effector/memory CD4^+^ T cells collected after 40 weeks of adult exposure to TCE was conducted. The analysis incorporated ∼337 770 CpGs sites that were assayed with at least 10× coverage. Bisulfite conversion efficiency in all samples was \> 99%. [Figure 1A](#dvx013-F1){ref-type="fig"} presents histograms showing the average methylation of all the CpG sites examined after binning for average methylation (e.g. 0--5% methylation or 20--25% methylation). These profiles demonstrated that 54.7% and 16.5% of CpG sites from control mice were hypomethylated (0--5% methylation) or hypermethylated (95--100% methylation), respectively. These values were slightly altered in CD4^+^ T cells from TCE-treated mice; with 54.2% hypomethylated and 15.9% hypermethylated CpG sites respectively. Representing the binned mean methylation results without the hyper- and hypo-methylation skewing the extreme ends of the histogram ([Fig. 1B](#dvx013-F1){ref-type="fig"}) illustrated TCE-induced differences in the percentage of CpGs methylated at 90--95% (4.9% vs 6.0%; *P* \< 0.05).

![Average DNA methylation levels of all CpGs interrogated. RRBS analysis of the effector/memory CD4^+^ T cells collected after 40 weeks of adult exposure to TCE was conducted. (**A**) Histograms show the average methylation of all 337 770 CpG sites examined in CD4^+^ T cells from either control or TCE-treated mice after binning for average methylation (e.g. 0--5% methylation or 20--25% methylation). (**B**) The same histograms are shown without inclusion of the CpGs that were either 0--5% or 95--100% methylated](dvx013f1){#dvx013-F1}

The average methylation levels of CpGs on individual chromosomes were also examined. With the exception of the X chromosome, most of the chromosomes showed very similar methylation profiles ([Fig. 2A](#dvx013-F2){ref-type="fig"}). In other words, most had similar percentages of CpGs with hypo-, hyper- and mid-range methylation levels, regardless of whether they came from CD4^+^ T cells from control or TCE-treated mice. Unlike the 19 autosomal chromosomes, very few (∼2.4%) of the CpGs interrogated in the X chromosome displayed methylation levels between 0 and 5%. Instead, the X chromosome had a slightly higher percentage (18.3%) of CpGs with mean methylation levels between 95 and 100%, and a considerably higher percentage (51%) of CpGs with mean methylation levels between 15 and 60%, peaking around 40% mean methylation. This effect was more visually striking after removing from the histograms all CpGs with 0--5% or 95--100% methylation ([Fig. 2B](#dvx013-F2){ref-type="fig"}). The difference in the average methylation histogram of the X chromosome was confirmed by Fractional Polynomial modeling ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). This modeling showed that the basic shape of the methylation distribution did not differ among representative autosomal chromosomes (chromosomes 1, 3 or 12), regardless of TCE exposure, but that all are different from the X chromosome. [Figure 2B](#dvx013-F2){ref-type="fig"} also reveals other apparent chromosome-specific differences in the shape of the methylation distribution histograms. For example, chromosome 17 has increased mid-range DNA methylation levels, while several other chromosomes (e.g. 16, 18 and 19) had flattened U-shape histograms indicated less skewing toward hypo- or hyper-methylation status. The chromosome-specific differences in CpG mean methylation appeared to be inherent, i.e. were not induced by TCE exposure.

![Chromosome-specific mean DNA methylation levels. (**A**) The results from the RRBS analysis described in [Fig. 1](#dvx013-F1){ref-type="fig"} were sorted into individual chromosomes, and presented after binning for average methylation of the CpGs. The area of each histogram was normalized to one to make it easier to compare the chromosomes. (**B**) The RRBS results were presented (as total number of CpG sites in the different bins) after excluding the CpG sites that were either 0--5% or 95--100% methylated](dvx013f2a){#dvx013-F2}

When the mean methylation of thousands of CpG sites was examined, as shown in [Figs 1 and 2](#dvx013-F1){ref-type="fig"}, no TCE-induced effect was detected. However, global effects on DNA methylation can also occur at the level of methylation variance \[[@dvx013-B47]\]. Methylation variance reflects the group-specific inter-sample variation in the methylation of each CpG site, rather than mean methylation of each CpG site. An examination of all the CpGs interrogated showed that mean methylation variance detected in effector/memory CD4^+^ T cells, regardless of TCE treatment, was substantially lower than the theoretical variance that would be achieved by random distribution in a percent mean methylation bin ([Fig. 3](#dvx013-F3){ref-type="fig"}). However, as we and others have previously reported, inter-sample methylation variance at the CpG sites examined in effector/memory CD4^+^ T cells correlated with distance to either end of the 0--100% methylation scale \[[@dvx013-B6], [@dvx013-B48]\]. Thus, mean methylation variance in both control and TCE samples was highest at those CpG sites that averaged 30--80% methylation ([Fig. 3](#dvx013-F3){ref-type="fig"}). Interestingly, exposure to TCE decreased the methylation variance at CpGs at almost all levels of mean methylation. This was true for the X chromosome as well, despite its different mean methylation distribution (data not shown). A likelihood test statistic of 75.8 (*P*-value \< 0.0001) suggested that the curves documenting methylation variance for all the CpGs interrogated ([Fig. 3](#dvx013-F3){ref-type="fig"}) are significantly different between the samples from control and TCE-treated mice. We evaluated the methylation variance for each of the CpG sites that averaged between 50 and 60% methylation for four individual control samples ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}). This revealed that the variance in the control group could not be attributed to an outlier sample, but appeared to represent a consistent difference among all the samples. Thus, the ability of TCE to impact CpG methylation on a genome-scale, as evidenced by this decrease in methylation variance, did not appear to be artefactual.

![TCE exposure decreased total methylation variance. The RRBS results for the effector/memory CD4^+^ T cells from control or TCE-treated mice were sorted by treatment group and binned for mean methylation. The inter-sample methylation variance at all the CpG sites in the different bins was then calculated. The dotted line represents a prediction of highest possible methylation variance based on a theoretical value spread of four samples in each bin](dvx013f3){#dvx013-F3}

Effects of TCE at the Individual CpG Level
------------------------------------------

In addition to assessing the genome-scale effects of TCE on DNA methylation, individual CpG sites that were differentially methylated by TCE exposure were identified. Comparison of effector/memory CD4^+^ T cells from control and TCE-treated mice revealed 233 differentially methylated sites (DMS, *q* value \< 0.005, and methylation differences ≥ 10%). Hierarchical clustering of the DMS is shown in [Fig. 4A](#dvx013-F4){ref-type="fig"}. Annotation of the DMS indicated that the 233 DMS were associated with 216 genes after taking into account those instances in which two or more CpGs were associated with the same gene. Further evaluation for potential functional significance narrowed down the list to 157 DMS that were actually located in a gene, or within 5 kb upstream of the transcription start site (TSS), and thus in a possible promoter region. As shown in [Fig. 4B](#dvx013-F4){ref-type="fig"}, more DMS were found downstream compared with upstream of the TSS. Distribution from TSS was not normally distributed (*P*-value of Shapiro--Wilk tests is \<0.001, rejects the null hypothesis which is data are normally distributed). Examination of symmetry plot and quantile--quantile plot shows that the data are heavy-tailed. The greatest number of DMS were located within 5 kB downstream of the TSS. Thus, TCE tended to alter methylation of CpG sites in the gene body close to the TSS more often than it altered sites in a traditional promoter region.

![Identification of CpG sites differentially methylated by TCE exposure. (**A**) RRBS analysis of effector/memory CD4^+^ T cells from control and TCE-treated mice revealed 233 DMS (methylation difference ≥ 10%, *q* value \<0.005). Hierarchical clustering of the gene-associated DMS is shown here. (**B**) The genomic location of the 233 DMS detected in the effector/memory CD4^+^ T cells relative to the nearest transcription start site (TSS) is shown. (**C**) The genes associated with the DMS identified by the RRBS were subjected to a gene list functional analysis by the Panther Gene Ontology Classification System](dvx013f4){#dvx013-F4}

Pathway analysis of the CpG sites differentially methylated by TCE indicated that, in terms of molecular function, TCE primarily altered methylation of genes associated with binding (GO:0005488) ([Fig. 4C](#dvx013-F4){ref-type="fig"}). Drilling down in the binding molecular function category showed that TCE effects were focused on genes associated with nucleic acid binding (GO:003676), that were in turn enriched for genes associated with DNA binding (GO:0003677). TCE also differentially methylated genes associated with protein binding (GO:0005515), specifically transcription factor binding activity (GO:0000988). Taken together, TCE exposure altered DNA methylation in a manner that seemed primed to impact epigenetic function and gene expression.

When the CpG sites that were differentially methylated between control and TCE samples were binned by average percent methylation in effector/memory CD4^+^ T cells from control mice the profile included many CpG sites with mid-range methylation ([Fig. 5](#dvx013-F5){ref-type="fig"}). The percentage of DMS with hypo-methylated (0--20%) and hyper-methylated (80--100%) status was much lower than those found in the evaluation of all the CpGs interrogated (as shown in [Fig. 2](#dvx013-F2){ref-type="fig"}). When the differentially methylated CpG sites were binned by average percent methylation in effector/memory CD4^+^ T cells from TCE-treated mice, it showed that, compared with controls, TCE decreased the number of CpG sites with 60--80% methylation, and increased the number of CpG sites that averaged 80--100% methylation. This suggested that the effect of TCE on DNA methylation was skewed toward inducing hyper- rather than hypo-methylation.

![Average percent methylation of CpG sites differentially methylated by TCE. RRBS analysis of effector/memory CD4^+^ T cells from control and TCE-treated mice revealed 233 DMS (methylation difference ≥ 10%, *q* value \< 0.005). These DMS were sorted separately for control and TCE-treated samples and binned for mean methylation](dvx013f5){#dvx013-F5}

Enrichment for Polycomb Protein Binding Sites
---------------------------------------------

A single CpG may indicate the DNA methylation status of the surrounding region in which differential methylation of other individual sites may not reach the level of statistical significance. Thus, alterations in methylation of single CpGs in regulatory regions can have potential functional importance. The Mouse NCB137/mm9 genome in the UCSC Genome Browser was used to determine whether the DMS were located in regulatory elements that bound transcription factors, and thus might impact transcription. Of the 233 DMS, 87 (37.3%) were found in regulatory elements with annotated transcription factor binding sites. Analysis of these 87 DMS revealed that 85% were found in regions exclusively used to bind one or more of four different Polycomb group (PcG) proteins, namely Ezh2, Suz12, Mtf2 or Jarid2 ([Fig. 6](#dvx013-F6){ref-type="fig"}; [Table 1](#dvx013-T1){ref-type="table"}). The remaining 15% DMS in regulatory regions were found in binding sites for other transcription factors (e.g. Ebf1, Gata1, Nfe212, and ATOH). This distribution was somewhat surprising since only ∼19 000 (4.5%) or the ∼399 000 unique transcription factor binding sites in the whole mouse genome are thought to bind one or more PcG protein. The TCE-induced modifications of CpG sites in the PcG protein binding regions were evenly divided between increased and decreased methylation. Of the DMS in polycomb binding sites, most (85%) flanked a TSS. In comparison, none of the DMS in binding sites for other transcription factors occurred in a region that flanked a TSS. Indeed, an evaluation of all 337 770 CpGs sites interrogated in the effector/memory CD4^+^ T cells revealed that only 23.2% were found in PcG protein binding regions, while only 7.2% were found in regulatory regions targeted by other transcription factors. Thus, our evaluation of effector/memory CD4^+^ T cells suggests that PcG protein binding regions are enriched for CpG sites. It is possible that the CpG sites in these regions of effector/memory CD4^+^ T cells may be particularly sensitive to TCE-induced alterations. Table 1:DMS found in genes or gene promoter regions (*q* value \< 0.005 and differential methylation ≥ 10%)ChrPositionDifference between TCE and control methylationRefseq IDFeature namePcGOther TF with PcGchr15273308719.80NM_133829Mfsd6NoneNonechr17287142810.11NM_008342Igfbp2NoneNonechr184692366--12.74NM_152915DnerMtf2chr18791512312.38NM_027029Spata3Mtf2, Suz12, EZH2, Jarid2chr18791517610.91NM_027029Spata3Mtf2, Suz12, EZH2, Jarid2chr188566769--11.67NM_010933NppcSuz12, EZH2, Jarid2chr19507901021.05NM_001310428Crocc2NoneNonechr105769543519.10NM_001081954DuxMtf2chr105934850138.10NM_019965Dnajb12NoneEbf1chr107062250112.01NM_031397Bicc1Mtf2, Suz12, EZH2, Jarid2chr108029755426.59NM_001013758Lingo3Mtf2, Suz12, EZH2chr108030650313.08NM_001013758Lingo3Mtf2, Suz12, EZH2chr10114239413--17.84NM_146241POL2Mtf2, Suz12, EZH2, Jarid2chr1012695484924.03NM_001098789Shmt2Nonechr10126962175--15.64NM_028230Nxph4Mtf2, Suz12chr10127733967--12.19NM_031252Il23aNonechr11849665822.56NM_001083587Tns3NoneNonechr1150416921--11.01NM_175643Adamts2Mtf2, Suz12, EZH2, Jarid2chr1153271010--23.32NM_027917Schroom1Mtf2, Suz12chr116126763127.93NM_009548Rnf112NoneNonechr1192958940--13.88NM_028296Car 10Mtf2, Suz12chr119569207229.58NM_025659Abi3Mtf2, Suz12, EZH2chr1110322290210.07NM_001205236h3d20Nonechr11113664146--20.41NM_172800Sdk2Nonechr11117829957--13.33NM_007707Socs3Nonechr1112169156522.39NM_029049Ptchd3Mtf2, Suz12chr122536654116.22NM_001004455Cys1Mtf2, EZH2chr122802669418.76NM_009234Sox11Mtf2, Suz12, EZH2chr125174948014.75NM_008858Prdk1Mtf2, Jarid2chr125174959422.12NM_008858Prdk1Mtf2, Jarid2chr127750605913.22NM_008301Hspa2Mtf2, Jarid2, EZH2, Jarid2chr128107137917.08NM_001252562Rad51bNoneEbf1chr1281216463--18.69NM_007564Zfp36l1Mtf2chr128179413520.44NM_001177503Plekhd1Mtf2, Suz12chr128482846027.36NM_001267625Dpf3Mtf2, Jarid2, EZH2, Jarid2chr128482846232.76NM_001267625Dpf3Mtf2, Jarid2, EZH2,Suz12chr128575859520.16NM_025525Bbof1NoneNonechr1286630006--21.49NM_172414Zc2hc1cNoneNonechr1211146861028.44NM_012023Ppp2r5cNoneNonechr1349168362--23.74NM_001290313Wnk2NoneNonechr1353560005--23.88NM_013601Msx2Mtf2chr1355097204--16.10NM_001206390Unca5NoneNonechr136913773817.13NM_153534Adcy2EZH2, Mtf2chr13104899736--10.66NM_029447N1nNoneNonechr13110249606--21.25NM_011056Pde4dNoneNonechr1455195182--22.04NM_010590AjubaNoneNonechr1464478548--26.58NM_028228Pinx1NoneNonechr157763733--10.39NM_001301333GdnfMtf2, Jarid2, EZH2, Suz12chr153975132626.27NM_172814Lrp12NoneNonechr1578548459--21.71NM_183141Elfn2Mtf2, Jarid2, EZH2, Suz12chr1578873745--10.38NM_015738Galr3Suz12, EZH2chr157992009322.09NM_009303Syngr1NoneNonechr159172991011.19NM_198927Muc19NoneNonechr15101858889--20.17NM_010664Krt18Mtf2chr152244083424.56NM_023794Etv5NoneNonechr166581553417.40NM_028572Vg113NoneATOH1chr167268209511.64NM_019413Robo1NoneNonechr168498907413.29NM_001198823AppNoneNonechr171180635826.52NM_016694Park2NoneNonechr1726204880--17.06NM_001162868Rab11fip3Mtf1chr172778777430.42NM_001286743Pascin1NoneNonechr173232633014.78NM_001033163Ephx3Mtf2chr173503356020.63NM_001286575Zbtb12NoneNonechr174780952026.89NM_198421Usp49NoneNonechr178011266710.22NM_009994Cyb1b1Mtf2, Jarid2, EZH2, Suz12chr178601454820.07NM_198421SIX30S1Mtf2, Jarid2, EZH2, Suz12chr187170227--15.42NM_001081393Armc4NoneNonechr181199767311.79NM_001146287Cables1Mtf2, Jarid2, EZH2, Suz12chr183792651426.30NM_033595Pcdhga12Suz12chr1846372273--16.68NM_178872Trim36Suz12, Mtf2chr1874603497--26.02NM_201600Myo5bEZH2, Mtf2chr1875980831--36.51NM_145356Zbtb7cMtf2, Jarid2, EZH2, Suz12chr195332047--28.01NM_139301Catsper1NoneNonechr194738861522.47NM_008018Sh3pxd2aNoneNonechr194738866124.44NM_008018Sh3pxd2aNoneNonechr2563628411.52NM_177343CamkidNoneNonechr23764911020.86NM_001163566Crb2Mtf2, Jarid2, EZH2, Suz12chr23764912120.12NM_001163566Crb2Mtf2, Jarid2, EZH2, Suz12chr27617625315.65NM_001081033PdellaMtf2chr291316809--23.84NM_172668Lrp4NoneNonechr29147566416.00NM_010168F2NoneNonechr2126379285--22.21NM_011978Slc27a2NoneNonechr2147874612--14.49NM_010446Foxa2Mtf2, Jarid2, EZH2, Suz12chr216524267716.72NM_054055Slc13a3NoneNonechr369120629--12.04NM_178726Ppm11Mtf2, Jarid2, EZH2, Suz12chr38922924912.43NM_001113331Shc1NoneNonechr312890612515.67NM_011098Pitx2Mtf2, Jarid2, EZH2, Suz12chr3151928358--26.03NM_199465NexnMtf2, Jarid2, EZH2, Suz12chr446728412--11.11NM_001081141Gabbr2NoneNonechr465065259--33.06NM_019514Astn2NoneNonechr48055786210.89NM_026821Lurap11NoneNonechr411792890915.15NM_011213PtprfNoneNonechr4124682634--26.36NM_138683Rspo1NoneNonechr4133430503--18.16NM_001285506Rps6ka1NoneNonechr413471134126.82NM_019732Runx3Suz12chr413471135023.31NM_019732Runx3Suz12chr4139379960--22.47NM_011039Pax7Mtf2, Jarid2, EZH2, Suz12chr4141640595--21.15NM_145402GM10565NoneNonechr414842361729.44NM_019781Pex14NoneNonechr414974586017.35NM_001085492RereNoneNonechr415108935026.29NM_001081557Camta1NoneNonechr415283416818.58NM_001099299Ajap1NoneNonechr53406641611.04NM_001163217Fgfr3Mtf2, Jarid2, EZH2, Suz12chr53718748010.53NM_026242Mrfap1NoneNonechr5114723943--11.11NM_148935Foxn4NoneNonechr512227867222.15NM_001306126Sh2b3Mtf2chr5131782939--23.02NM_145218Wbscr17Mtf2, Jarid2, EZH2, Suz12chr514044798917.64NM_175522Rlfn1NoneNonechr5148138165--13.33NM_001039678UradNoneNonechr623210525--18.28NM_028462Cadps2Mtf2chr66320747817.79NM_008167Grid2Mtf2, Jarid2, EZH2, Suz12chr683135914--26.38NM_007835Dctn1NoneNonechr685324297--10.98NM_001003955Rab11fip5NoneNonechr69892636430.44NM_001197322Foxp1NoneNonechr611334277533.59NM_133923Tt113NoneNonechr6125262312--21.28NM_010736TltprMtf2chr713628786--15.20NM_145819Mzf1Suz12, Mtf2chr716726237--11.83NM_148946Slc8a2NoneNonechr724096775--16.75NM_001004194NirpfeNoneNonechr729606786--24.74NM_016772HnrnplNoneEbf1chr73501517613.38NM_008155Gpi1NoneNonechr75294012718.03NM_001289693Sec1/Ntn5NoneNonechr763520836--24.05NM_021879Oca2NoneNonechr787481393--12.53NM_133952Unc45aNoneNonechr79330139928.53NM_001102578Vmn2r75NoneNonechr710437631621.11NM_001177412Gab2NoneNonechr713395753427.42NM_026884Fam57bNoneATOH1chr7138078229--22.20NM_019564Htra1Mtf2, EZH2, Suz12chr812430585--10.48NM_009233GM5607Mtf2chr87240658818.95NM_026818Cilp2Mtf2, Jarid2, EZH2, Suz12chr87289869914.06NM_016685CompMtf2, EZH2, Suz12chr873296263--11.49NM_008841Pik3r2NoneNonechr883263159--24.64NM_053124Smarca5NoneNonechr894882246--12.94NM_018826Irx5Mtf2, EZH2, Suz12chr8107880886--12.28NM_001081332Slc9a5NoneNonechr811672981613.57NM_173016Vat1lMtf2, Suz12chr8121971793--19.02NM_054095Necab2Jarid2, EZH2, Suz12chr812508890026.17NM_026014Cdt1NoneEbf1chr8125389116--36.05NM_007662Cadherin 15NoneEbf1chr8125389194--30.65NM_007662Cadherin 15NoneEbf1chr8125389244--29.38NM_007662Cadherin 15NoneEbf1chr8125389246--28.44NM_007662Cadherin 15NoneEbf1chr92154957912.84NM_026282LdlrNoneNonechr931720357--14.51NM_013800Barx2Jarid2, EZH2, Suz12chr956994574--14.04NM_028347Neil1NoneNonechr9107611227--21.43NM_011349Sema3fMtf2, EZH2, Suz12chrX11655662--14.96NM_029510BcorMtf2, Jarid2, EZH2, Suz12chrX11658411--23.91NM_175046BcorMtf2, Jarid2, EZH2, Suz12chrX3441504022.79NM_019668Ube2aNoneNonechrX3441507721.67NM_019668Ube2aNoneNonechrX5638727027.18NM_010200Fgf13Mtf2, EZH2chrX68917537--24.71NM_010340Gpr50Mtf2, Jarid2, EZH2, Suz12chrX9745407121.48NM_001177943EdaNoneNonechrX11041227823.36NM_033605Dach2NoneNonechrX13022171630.33NM_001105245Pcdh19Mtf2, Jarid2, Suz12chrX158346841--25.22NM_198409NhsNoneNonechrX16034712127.82NM_001290379Ap1s2NoneNone

![Many CpG sites differentially methylated by TCE are found in PcG protein binding sites. RRBS analysis of effector/memory CD4^+^ T cells from control and TCE-treated mice revealed 233 DMS (methylation difference ≥ 10%, *q* value \< 0.005). Annotation of these DMS described whether they were found outside of a transcription binding site (NRE: no regulatory element), or in a regulatory element that bound PcG proteins or other transcription factors. The percentage of CpG sites differentially methylated by TCE was compared with 400 randomly selected CpG sites not altered by TCE (Random CpGs), and to the total number of individual OREG sites known to bind Suz12, EZH2, Mtf2 or Jarid2 or other transcription factors (as identified in Mouse NCB137/mm9 genome in the UCSC Genome Browser) (All Regulatory Elements in Genome)](dvx013f6){#dvx013-F6}

TCE Alters CD4^+^ T-Cell Gene Expression
----------------------------------------

The functional effects of TCE exposure were further assessed at the gene expression level. This was accomplished using a microarray assessment of the same cells as those profiled in the RRBS analysis: i.e. effector/memory (CD62L^lo^) CD4^+^ T cells collected from control mice or from mice exposed to TCE for 40 weeks. Gene expression was examined 20 h after activation of the CD4^+^ T cells *in vitro*. At a cutoff of FDR \< 0.05 and a fold-change \> 1.25, the expression of ∼560 genes was found to be significantly altered in the activated effector/memory CD4^+^ T cells of mice exposed to TCE compared with similarly activated effector/memory CD4^+^ T cells from control mice (data not shown). Of these differentially expressed genes, those associated with immune function are listed in [Table 2](#dvx013-T2){ref-type="table"}. A network evaluation suggested that pathways with the most number of genes altered by TCE after 40 weeks were those with decreases in gene expression that centered on *Ifng* and *Tnf* ([Supplementary Fig. S3A](#sup1){ref-type="supplementary-material"}). qRT-PCR analysis confirmed the TCE-induced decrease in the expression of *Ifng* and *Tnf* in the effector/memory CD4^+^ T cells ([Supplementary Fig. S3B](#sup1){ref-type="supplementary-material"}). Of the genes altered by TCE in the effector/memory CD4^+^ T cells, none contained the previously described DMS. Table 2:TCE vs Control annotated immune gene expressionSymbolREFSEQ_IDFC*P* valueadj. *P* value*q*-ValuePcGOther TF with PcG**Cytokines**Ifit2NM_008332.2--2.914226.49E--060.0089010.007645NoneCdx1, Myod1TnfNM_013693.1--2.437093.44E--050.0159260.01368NoneNoneIfitm3NM_025378.2--2.041880.0001980.0310750.026692NoneStat5aAmica1NM_001005421.3--2.012040.0001280.0257260.022097NoneNoneIfi202bNM_008327.1--2.004141.99E--060.0054470.004679NoneNoneIl4NM_021283.1--1.982150.000380.0419710.03605NoneNfatc2Ifitm1NM_026820.2--1.868470.000390.042520.036523NoneNoneIrf7NM_016850.2--1.842920.0006570.0547560.047032NoneNoneIsg20NM_020583.4--1.752961.48E--050.0118390.010169NoneFoxa2Il17aNM_010552.3--1.687940.0007930.0602670.051766NoneBhlhe40LifNM_001039537.1--1.504541.05E--050.010610.009113NonePax6Il16NM_0105511.3058696.96E--070.003940.003384NoneFoxa2, ATOH1Tnfrsf26NM_175649.51.3468370.000320.0388260.03335NoneCdx1Ing4NM_133345.21.3664420.0006340.0542380.046587NoneRxra, Sox3Traf1NM_009421.31.4012210.0008370.0621560.053389NoneBhlhe40, Myod1Ncf4NM_008677.11.4054978.09E--050.0219650.018867NoneEbf1, Myod1, Bhlhe40Il1r2NM_010555.41.4599210.000520.0491570.042223NoneFoxa2**Chemokines**Cxcl10NM_021274.1--1.764650.0002190.0327330.028116NoneNoneCcrl2NM_017466.4--1.660051.25E--050.0107250.009212NoneNoneCxcr4NM_009911.21.6348430.0003340.0205020.016849Suz12, Jarid2, Mtf2ATOH1**Transcription factors & enzymes**Mycbp2NM_207215.2--1.643820.0001890.0303470.026066Mtf2Meis1, Bhlhe40, Ebf1Trafd1NM_172275.1--1.586437.10E--050.0214670.018439NoneFoxa2, Nkx2-5Sp100NM_013673.2--1.312150.0003770.0419210.036008NoneBhlhe40, Cdx1Cxxc1NM_028868.31.3212147.64E--050.0219650.018867NoneBhlhe40CskNM_007783.21.3442700.00037040.0418610.035956NoneEbf1, ATOH1Mapk11NM_011161.41.3418710.0002380.0340050.029208NoneEgr2, Sox3Rap1gapNM_001081155.11.3448910.0007920.0602670.051766Mtf2Bhlhe40Elk3NM_205536.11.37911.47E--050.0118390.010169NoneEbf1, Stat5aNfkbibNM_010908.31.4102980.0001190.0254780.021884NoneFoxa2Rag1ap1NM_009057.21.420480.0001580.0271650.023333NoneEbf1Mt1NM_013602.22.125397.29E--060.0094470.008114NoneNone**Cell cycle**Gadd45gNM_011817.1--1.301097.79E--050.0219650.018867Suz12, Mtf2ATOH1Cdc23NM_1783471.3401615.13E--060.00830.007129NoneFoxa2**Apoptosis**DaxxNM_007829.3--1.791083.82E--050.0160240.013764NoneNoneFaslNM_010177.3--1.453560.0001150.0252940.021726NoneCdx1Bcl11bNM_021399.21.3115080.0002620.0353760.030386EZH2, Suz12, Jarid2, Mtf2Pdcd2NM_008799.21.3567543.22E--060.0069020.005928NoneBhlhe40, Meis1Pdcd4NM_011050.31.4074550.0005460.050120.04305NoneFoxa2, Myod1**Integrins**Sdc3NM_011520.3--1.843890.0002080.0316290.027168NoneHoxc9, Sox3Ly6c1NM_010741.2--1.501910.0001460.0260130.022343NoneCdx1, Bhlhe40Cd247NM_031162.11.3007880.0002030.0312160.026812NoneFoxa2, Creg1, Tal1Leng9NM_175529.31.3033160.0004440.0450170.038667Mtf2NoneMic2l1NM_138309.11.336179.20E--050.0228780.019651NoneStat5aHist1h2aiNM_178182.11.4191970.0008980.0633080.054378NoneNoneHist1h1cNM_015786.11.5928850.0006220.0541580.046519NoneCdx1, Bhlhe40Ctla4NM_009843.31.4727010.0002210.032840.028208NoneNone**Miscellaneous**Birc2NM_007465.11.3728561.75E--050.0127940.010989NoneRxra, Cdx1Ddb2NM_028119.41.374041.22E--050.0107250.009212NoneCdx1, Rxra, Tal1Rfx1NM_009055.21.5199090.0001010.0239460.020568NoneMyod1

Although TCE-induced gene changes and DMS did not coincide they did share some common features. Evaluation of the first intron and 5 kb region upstream of the TSS for the immune genes altered by TCE ([Table 2](#dvx013-T2){ref-type="table"}) showed that 10.2% had binding sites for PcG proteins, while an additional 69.4% had binding sites for other transcription factors that were in turn regulated by PcG proteins at their own TSS. This suggests that at least 80% of the genes altered by TCE in the effector/memory CD4^+^ T cells had the potential for PcG protein regulation.

Discussion
==========

Our RRBS evaluation of CpG methylation distributions in autosomal chromosomes in effector/memory CD4^+^ T cells conformed to the general trend: hypomethylation \> hypermethylation \> mid-range methylation. On a genome-scale TCE appeared to decrease methylation variance of CpG sites that averaged \<95%, or \>5% methylation. Increased methylation variance at CpG sites that average between 30 and 60% methylation is thought to be important for maintaining flexibility in the methylation and associated expression of functionally important genes \[[@dvx013-B47]\]. Such regions may be protected from suppressed, fully methylated states or permissive, unmethylated states. When we examined all the CpGs interrogated by RRBS in the effector/memory CD4^+^ T cells from control mice, the variance was highest for CpGs with intermediate methylation levels. This has been described previously \[[@dvx013-B6]\] and is related to the fact that percentage scales tend to restrict variability near the edges of the scale. In the current study, we found that TCE exposure decreased variance in CpG sites with intermediate methylation levels. The ability of TCE to impact intermediate methylation may have more functional significance than effects at the ends of the methylation scale; increasing DNA methylation from 5 to 20%, or decreasing methylation from 95 to 80% is less likely to alter gene expression.

Using a methylation difference of 10% between the two groups as the cutoff, only 233 CpGs (216 genes) of the 337 770 CpGs interrogated in effector/memory CD4^+^ T cells were differentially methylated by TCE exposure. The relatively small TCE affect (0.07% of the CpGs examined) compares to the 0.83% of total CpGs that were found to be differentially methylated when naïve CD4^+^ T cells were contrasted to memory CD4^+^ T cells in humans \[[@dvx013-B24]\]. It is perhaps not surprising that two populations of effector/memory CD4^+^ R cells that differed only in relatively low level adult exposure to a toxicant would demonstrate less epigenetic modifications than that which accompanies CD4^+^ T cell differentiation. A transcriptomic analysis of the same effector/memory CD4^+^ T cells used to generate the RRBS data identified a number of immune-associated changes following TCE exposure. However, none of the differentially expressed genes overlapped with DMS in the CD4^+^ T cells from the TCE-treated mice despite the fact that many of the DMS were found in gene bodies within 5 kb downstream of the TSS. Although cytosine methylation of promoters is negatively correlated with gene expression, the question of whether methylation of a particular cytosine impacts expression is still unclear. Others have also seen a lack of correlation between gene expression and treatment-related changes in methylation status \[[@dvx013-B49]\]. In one study of over 230 000 cytosines, only 16.6% demonstrated a significant association between methylation and expression of a closely located TSS \[[@dvx013-B54]\]. The association between gene body methylation and gene expression appears to be complex and context dependent \[[@dvx013-B55], [@dvx013-B56]\]. Even in cancerous cells with their often more robust changes in methylation, associations between gene expression and methylation are surprisingly small, and include both positive and negative correlations \[[@dvx013-B57]\]. This may be attributed to the time-dependent sensitivity of gene expression. Alternatively, the epigenetic impact of exogenous factors such as TCE on gene expression may be indirect; via methylation-induced changes in the expression or function of some upstream regulator, and thus not obviously correlative. Alterations in methylation may only play a permissive, rather than direct, role in regulating gene expression.

Compared with the 19 autosomal chromosomes, the X chromosome had a very different profile of mean methylation levels, regardless of TCE exposure. In dramatic contrast to the autosomal chromosomes the X chromosome had very few hypomethylated CpG sites, and a much larger percentage of CpG sites with mid-range DNA methylation. Differences in X chromosome DNA methylation profiles are not surprising due to the epigenetically regulated X chromosome silencing that occurs in the blastocyst. This silencing is accomplished by a combination of epigenetic modifications involving histone deacetylation, RNA methylation, and DNA methylation \[[@dvx013-B58], [@dvx013-B59]\]. Comparing the methylation status of individual CpGs in the X chromosome from peripheral blood leukocytes of males and females indicated both had a set of highly methylated CpGs, while CpGs that were hypomethylated in males (under 11%) tended to be methylated in the 30--40% range in females \[[@dvx013-B60]\]. This is largely in agreement with our analysis of the X chromosome from effector/memory CD4^+^ T cells of female mice. The mean methylation distribution observed in the X chromosome does not reflect averaging of two chromosomes, one of which was completely hypermethylated. Instead, the profile indicates the presence of a more complex methylation pattern. It remains to be determined whether this pattern is due to the DNA methylation on the inactivated X chromosome, the active X chromosome, or a combination of both.

One surprising result was the apparent connection between TCE-altered CpGs and PcG protein binding regions. PcG proteins were first identified as regulators of embryonic development and stem cell pluripotency \[[@dvx013-B61]\]. PcG proteins form two complexes in mammals; polycomb-repressive complex 1 (PRC1) and PRC2. PRC2 mediates H3K27me3, which is thought to inhibit transcription by a mechanism involving H2A ubiquitination and/or chromatin compaction \[[@dvx013-B62], [@dvx013-B63]\]. The initial work on PcG proteins conducted in embryonic stem cells identified a complex interaction between PRC2 binding and DNA methylation. Although the majority of CpG islands do not normally recruit PcG proteins, there is an anomalous conservation of CpG sites at PRC2-binding domains \[[@dvx013-B64], [@dvx013-B65]\]. This connection seems to involve a certain level of reciprocal regulation. For example, PRC2 binding represses DNA methylation at the PRC2 target regions in embryonic stem cells \[[@dvx013-B66]\]. Similarly, DNA methylation appears to regulate PRC2 binding. A high density of unmethylated CpG sites reportedly promotes PcG protein binding \[[@dvx013-B67]\]. Removal of DNA methylation promotes the accumulation of the PRC2 complex in inappropriate genomic loci, indicating that DNA methylation is capable of attenuating PRC2 binding \[[@dvx013-B68]\]. However, there is evidence in somatic cells and cancer cells that DNA methylation and PRC2 binding may not be mutually exclusive, and may in fact work together to suppress specific gene expression \[[@dvx013-B65]\].

The role of PcG proteins in the regulation of immune function specifically is still being defined. Late stages of human B cell differentiation showed methylation gain at PcG-repressed areas, thus suggesting a need for DNA methylation to block PcG protein binding in non-transformed lymphocytes \[[@dvx013-B69]\]. In terms of T cells, PcG proteins have been shown to form a complex with the Ikaros transcription factor to regulate thymocyte development \[[@dvx013-B70]\]. They can also regulate the function of mature peripheral T cells \[[@dvx013-B71]\]. For example, EZH2, a component of PRC2, has recently been shown by others to be highly expressed in CD4^+^ T cells \[[@dvx013-B72]\], where it reportedly associates with Foxp3 to mediate gene repression and suppressive function \[[@dvx013-B73]\]. Loss of EZH2 *in vivo* caused increase immune pathology, including colitis, in part due to a lack of functional Treg cells \[[@dvx013-B73], [@dvx013-B74]\]. EZH2 also controls differentiation and plasticity of CD4^+^ Th1 and Th2 cells by binding and controlling expression of Tbx21 and Gata3 \[[@dvx013-B75]\]. Deletion of EZH2 leads to increased generation of effector/memory CD4^+^ T cells with an increased production of effector cytokines including IFN-γ \[[@dvx013-B73]\]. Cell differentiation is accompanied by losses and gains of H3K27me3 at many promoters at many stages of the process, while DNA methylation is altered at only a relatively small number of promoters during differentiation. This suggests that PcG protein binding represents a more robust suppression than DNA methylation.

There were some limitations associated with the current study. RRBS analysis does not distinguish between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). The ten-eleven translocation (TET) family of proteins can oxidize 5mC to 5hmC, a mark not effectively maintained by Dnmt1, thus leading to demethylation as cells divide. Polarization of CD4^+^ T cells toward Th1 and Th2 lineages is accompanied by changes in 5hmc-mediated DNA de-methylation of key genes \[[@dvx013-B76]\], and defects in DNA hydroxymethylation have been demonstrated in both thymocytes and peripheral CD4^+^ T cells from patients with autoimmune diseases \[[@dvx013-B77], [@dvx013-B78]\]. A direct correlation between levels of 5hmc and H3K27me has been described in a variety of somatic tissues \[[@dvx013-B79]\]. It will be important to distinguish whether the enrichment of PcG protein binding sites in the current study are associated with TCE-induced alterations DNA methylation or DNA hydroxymethylation.

Despite its limitations, the current study has demonstrated effects of TCE on genome-wide and gene-specific DNA methylation. This included a TCE-induced decrease in methylation variance, and the observation that TCE-induced changes in CpG methylation tended to occur in regulatory elements that bound suppressive PcG proteins. These effects may be mechanistically important since many autoimmune diseases are driven by effector/memory CD4^+^ T cells which are resistant to several mechanisms designed to guard against the expansion of autoreactive CD4^+^ T cells. Thus, any epigenetic mechanism that targeted effector/memory CD4^+^ T cells could have important functional consequences. Activation and subsequent gene expression in CD4^+^ T cells is a complex process. Aside from epigenetic mechanisms such as DNA methylation and histone acetylation, this process is also regulated by the levels and/or phosphorylation state of transcription factors and other signaling molecules. Understanding the contribution of all these factors toward CD4^+^ T cell activation is going to require complex modeling. The epigenetic alteration of polycomb protein binding may be another component in this process. The possibility that TCE alters DNA methylation in PcG protein binding sites, suggests that an associated alteration in PRC2 binding, and downstream upregulation of proinflammatory Th1 cytokines could play a role in the ability of TCE to promote autoimmunity.
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